Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial

Giant cell tumor of bone (GCTB) is a rare primary bone tumor, characterized by osteoclast-like giant cells that express receptor activator of nuclear factor-kappa B (RANK), and stromal cells that express RANK ligand (RANKL), a key mediator of osteoclast activation. A RANKL-specific inhibitor, denosu...

Ausführliche Beschreibung